Skip to content
Research Article Open access CC BY 4.0

Immune Response and Vaccine Strategies in Leishmaniasis: Insights and Challenges

Angel Justiz-Vaillant, Rodolfo Arozarena-Fundora, Darren Gopaul, Chandrashekhar Unakal, Sachin Soodeen, Reinand Thompson, Odalis Asin-Milan

South Asian Journal of Parasitology · pp. 93–109 · Published 21 Apr 2025

10.9734/sajp/2025/v8i2216

Abstract

Leishmaniasis, comprising cutaneous, mucocutaneous and visceral forms, is a parasitic disease caused by Leishmania species via sandfly bites, leading to skin ulcers and mucosal damage. Traditional treatments include antiparasitic drugs such as pentavalent antimonials, amphotericin B, and miltefosine, with immunotherapy and chemotherapy being explored for enhanced efficacy and reduced relapse. Mucocutaneous leishmaniasis (ML) balances IFN-γ and IL-10, affecting severity, while cutaneous leishmaniasis (CL) shows varied IFN-γ/IL- 10 ratios influencing prognosis. Cytokines and chemokines are diagnostic and prognostic markers in CL. Research into neutrophils and the NLRP3 inflammasome informs Th1/Th2 response regulation. Live attenuated LdCen-/- parasites and genetically modified vaccines show promise, with miR-21 as a potential efficacy biomarker. Understanding cytokine networks is crucial for new treatment strategies.

Leishmaniasis immune system vaccines cytokines biomarkers

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.